1. PURPOSE
	1. This policy establishes the [Organization]’s Human Research Protection Program (HRPP) and its commitment to protect the rights and welfare of human subjects.
2. POLICY
	1. Scope
		1. The HRPP applies to:
			1. All <Human Research> which engages the [Organization] as defined by “WORKSHEET: Engagement (HRP-422).”
			2. All <Human Research> submitted to the IRB for review.
		2. <Human Research> may not commence until IRB approved.
		3. Activities that are not <Human Research> do not require IRB review unless there is uncertainty whether the activity is <Human Research>.
		4. Direct questions about whether an activity (such as classroom research, quality improvement, case reports, program evaluation, or surveillance activities) represents <Human Research> to the IRB. The IRB provides written determinations in response to written requests.
		5. Direct questions about whether an organization is engaged in <Human Research> to the IRB. The IRB provides written determinations in response to written requests.
		6. After a study is completed, the [Organization] does not consider the return of results to former subjects to be <Human Research>.
	2. Ethical Principles
		1. The [Organization] follows the ethical principles described in the report “Ethical Principles and Guidelines for the Protection of Human Subjects of Research” also known as “The Belmont Report.” (see Reference 1)
		2. The [Organization] applies its ethical principles to all <Human Research> regardless of support or geographic location.
			1. Policies and procedures applied to research conducted domestically are applied to international research.
		3. The following categories of individuals are expected to abide by these ethical requirements:
			1. Investigators (whether professional or student)
			2. Research staff
			3. IRB members, IRB chairs, and IRB vice-chairs
			4. HRPP staff members
			5. [Organizational Official]
			6. Employees and agents
		4. Clinical trials should be conducted in accordance with the ethical principles in Reference 1 that have their origin in the Declaration of Helsinki and are consistent with good clinical practice and the applicable regulatory requirements.
	3. Review and Oversight Requirements
		1. The [Organization] applies FDA regulations, the <Original Rule>, the <Revised Rule>, and 45 CFR §46 Subparts B, C, and D as described in the Tables in the References section.
		2. The [Organization] applies the following requirements to non-exempt <Human Research as Defined by HHS> that is conducted, supported, or otherwise subject to regulation by the following federal departments or agencies:
			1. DOD: 10 USC 980, DOD Instruction 3216.02, OPNAVINST 5300.8B, and SECNAVINST 3900.39D
			2. DOE: DOE Order 443.1A and used “Checklist for IRBs to Use in Verifying That HS Research Protocols Are in Compliance with the Department of Energy (DOE) Requirements”.
			3. DOJ: 28 CFR §22 and 28 CFR §512.
			4. ED: 34 CFR §97 Subpart D (equivalent to 45 CFR §46 Subpart D), 34 CFR §98, 34 CFR §99, and 34 CFR §356.
			5. EPA: 40 CFR §26 and EPA Order 1000.17 Change A1.
		3. The [Organization] applies 45 CFR §46 Subparts B, C, and D to the extent required by OHRP[[1]](#footnote-2) to all non-exempt <Human Research as Defined by HHS>.
		4. The [Organization] commits to apply the “International Conference on Harmonisation – Good Clinical Practice E6.” (ICH-GCP) to <Human Research> evaluating the safety or effectiveness of a drug or biologic in countries outside of the United States.
			1. For all other <Human Research> evaluating the safety or effectiveness of a drug or biologic solely in the United States, the [Organization] commits to apply the “International Conference on Harmonisation – Good Clinical Practice E6.” (ICH-GCP) to the extent that it is compatible with HHS and FDA regulations.
			2. The guideline applies to interventional clinical trials of investigational products that are intended to be submitted to regulatory authorities.
			3. This guideline may also be applicable to other interventional clinical trials of investigational products that are not intended to support marketing authorization applications in accordance with local requirements.
				1. If applicable, policies and procedures should describe whether there are additional local requirements.
			4. Clinical trials should be designed and conducted in ways that ensure the rights, safety and well-being of participants.
			5. The rights, safety and well-being of the participants are the most important considerations and should prevail over the interests of science and society.
		5. The [Organization] applies all policies and procedures applied to research conducted domestically to research conducted in other countries, including:
			1. Confirming the qualifications of investigators for conducting the research
			2. Conducting initial review, continuing review, and review of amendments to previously approved research
			3. Post-approval monitoring
			4. Handling of complaints, non-compliance, and unanticipated problems involving risks to subjects or others
			5. Consent process and other language issues
			6. Ensuring all necessary approvals are met
			7. Coordination and communication with local IRBs
			8. Encompassing activities that are “research involving human participants” as defined by local laws.
		6. This [Organization] prohibits payments to professionals in exchange for referrals of potential subjects (“finder’s fees”).
		7. This IRB reviews payments designed to accelerate recruitment that are tied to the rate or timing of enrollment (“bonus payments”) and does not allow them unless the possibility of coercion and undue influence is minimized.
		8. The [Organization] does not conduct classified human subjects research or human subjects research involving the testing of chemical or biological agents, as discussed in DOD Instruction 3216.02.
		9. For human subjects research on DoD personnel, the Primary Investigator (possibly in conjunction with officials within the Office of the Vice President for Research) is responsible for coordinating with the additional bodies (e.g., the Information Management Control Officer) within the DoD as applicable to the research.
	4. Components of the HRPP
		1. [Organizational Official]
			1. The [Organizational Official] is the leader of the HRPP.
			2. The [Organizational Official] is authorized to:
				1. Allocate HRPP resources
				2. Appoint and remove IRB members, IRB chairs, and IRB vice-chairs
				3. Bind HRPP policies on the [Organization]
				4. Determine what IRBs the [Organization] will rely upon
				5. Disapprove, suspend, or terminate <Human Research>
				6. Hire and fire HRPP staff members
				7. Limit or condition privileges to conduct <Human Research>
				8. Prohibit publication of research
				9. Require destruction of research samples or data
				10. Determine that information represents <Serious Noncompliance>, <Continuing Noncompliance>, an <Unanticipated Problem Involving Risks to Subjects or Others>, a <Suspension of IRB Approval>, or a <Termination of IRB Approval>
				11. Act against employees related to <Serious Noncompliance> or <Continuing Noncompliance>
				12. Sign IRB authorization agreements
				13. Suspend or terminate <Human Research>
			3. The [Organizational Official] is responsible to:
				1. Oversee the HRPP
				2. Ensure the independence of the review process
				3. Ensure that complaints and allegations regarding the HRPP are appropriately handled
				4. Ensure that the HRPP has sufficient resources, including IRBs, appropriate for the volume and types of <Human Research> reviewed, so that reviews are accomplished in a thorough and timely manner
				5. Establish a culture of compliance with HRPP requirements
				6. Investigate and correct allegations and findings of undue influence on the <Human Research> review process
				7. Investigate and correct systemic problems related to the HRPP
				8. Periodically review HRPP policies and procedures
				9. Periodically review HRPP resources
				10. Review and sign federal assurances (FWA) and addenda
				11. Report to AAHRPP as soon as possible but generally within 48 hours of becoming aware of:

Any negative actions by a government oversight office, including, but not limited to, OHRP Determination Letters, FDA Warning Letters, FDA 483 Inspection Reports with official action indicated, FDA Restrictions Placed on IRBs or Investigators, and corresponding compliance actions taken under non-US authorities related to human research protections.

Any litigation, arbitration, or settlements initiated related to human research protections.

* + 1. All employees and agents of the [Organization]:
			1. All employees and agents of the [Organization] ultimately report to the [Organizational Official] for HRPP issues.
			2. All employees and agents of the [Organization] are responsible to:
				1. Be aware of this policy.
				2. Be aware of the definition of <Human Research>.
				3. Consult the IRB when there is uncertainty about whether an activity is <Human Research>.
				4. Not conduct <Human Research> without IRB approval.
				5. Report allegations of undue influence related to the HRPP.
				6. Report <Allegations of Noncompliance> or <Findings of Noncompliance>.
		2. IRB members and HRPP staff members
			1. IRB members, IRB chairs, IRB vice-chairs, and HRPP staff members are responsible to:
				1. Follow HRPP policies and procedures
				2. Undergo initial training, including training on specific federal agency requirements (e.g., DOD) when such research is reviewed
				3. Participate in continuing education activities at least annually, including training on specific federal agency requirements (e.g., DOD) when such research is reviewed
				4. Respond to contacts from participants or others
				5. Ensure contacts from participants or others are reported to the IRB when required by the IRB’s written procedures
				6. Ensure research submitted to an external IRB meets local requirements
				7. Ensure research approved an external IRB has all local approvals before being conducted
				8. Make “BROCHURE: Should I Take Part in Research (HRP-900)” available to research staff to provide to subjects
			2. IRB chairs are authorized to suspend or terminate <Human Research>.
			3. IRB members and HRPP staff members ultimately report to the [Organizational Official] for HRPP issues.
		3. IRB
			1. The [Organization] may rely upon the IRB of another organization provided an Institutional Authorization Agreement (IAA) is in place and one of the following is true:
				1. The IRB is part of an AAHRPP-accredited organization.
				2. All <Interventions> and <Interactions> occur at another organization.
				3. The [Organization] is engaged in <Human Research> solely because it receives funding directly from a federal department or agency.
				4. The IRB is not part of an AAHRPP-accredited organization, but the following has been determined via communication with the reviewing IRB:

The reviewing IRB adheres to the ethical principles described in the Belmont Report or an equivalent

The reviewing IRB has a current FWA

The [Organization] evaluates policies and procedures of the reviewing IRB proportional with the extent of risk associated with the study, as adequate

* + - 1. The IRB has the authority:
				1. To approve, require modifications to secure approval, and disapprove all <Human Research> activities overseen and conducted by the [Organization]
				2. To suspend or terminate approval of <Human Research> not being conducted in accordance with HRPP requirements or that had been associated with unexpected serious harm to participants
				3. To observe, or have a third party observe, the consent process and the conduct of the <Human Research>.
				4. Determine whether an activity is <Human Research>.
				5. Determine whether the [Organization] is engaged in <Human Research>
				6. To decide whether financial interests <Related to the Research> and the management, if any, allow approval of the <Human Research>
				7. To continue tracking all open <Human Research>, even when continuing review is not required.

This is accomplished by the IRB tracking ongoing <Human Research> via an institution-wide electronic submission and review system and post-approval monitoring efforts as described in “SOP: Post-Approval Monitoring (HRP-145).”

* + - 1. The [Organization] cannot approve <Human Research> that the IRB has not approved.
			2. External organizations relying on the [Organization]’s IRB can expect the [Organization’s] IRB to do the following and when the [Organization] relies on an external IRB the [Organization] expects the external IRB to do the following:
				1. Determine whether an activity is <Human Research>.
				2. Determine whether <Human Research> engages the [Organization].
				3. Determine whether the relying organization applies its FWA to some or all research and ensuring the review is consistent with requirements in the relying organization’s FWA.
				4. Determine which persons are considered engaged (agents) in the <Human Research>.
				5. Assure all IRB members, IRB Chairs and Vice Chairs are trained in accordance with applicable IRB SOPs.
				6. Evaluate scientific or scholarly validity of proposed research.
				7. For applicable clinical trials, assure ICH-GCP guidelines are met, including whether the available non-clinical and clinical information on an investigational product is adequate to support the clinical trial.
				8. Identify any relevant local, state, or international requirements related to <Human Research>, and apply AAHRPP criteria to international research.

Additionally, the [Organization] will identify any local requirements or local research context issues relevant to the research and communicate them to reviewing IRB, as requested.

* + - * 1. Make contact information for the IRB available to current and former subjects.
				2. Explain to subjects how to contact someone independent of the investigator for questions, concerns, complaints, or subject rights, or to offer input.
				3. Assure individuals with knowledge of community-based participatory research attend meetings where such research is reviewed.
				4. Evaluate and manage <Unanticipated Problems Involving Risks to Subjects or Others>, <Noncompliance>, <Serious Noncompliance> and <Continuing Noncompliance>, including when necessary to conduct an audit.
				5. Determine whether each allegation of noncompliance has a basis in fact and whether each incident of noncompliance is serious or continuing, including when necessary to conduct an audit.
				6. Manage <Unanticipated Problems Involving Risks to Subjects or Others>, <Noncompliance>, <Serious Noncompliance> and <Continuing Noncompliance>, <Suspension of IRB Approval> and <Termination of IRB Approval>.
				7. When appropriate, collaborate with the [Organization] to Manage <Unanticipated Problems Involving Risks to Subjects or Others>, <Noncompliance>, <Serious Noncompliance> and <Continuing Noncompliance>, <Suspension of IRB Approval> and <Termination of IRB Approval>.
				8. Notify the FDA of any <Unanticipated Problems Involving Risks to Subjects or Others>, <Serious Noncompliance> and <Continuing Noncompliance>, <Suspension of IRB Approval> and <Termination of IRB Approval.
				9. Collaborate with the [Organization] to notify regulatory agencies other than the FDA of any <Unanticipated Problems Involving Risks to Subjects or Others>, <Serious Noncompliance> and <Continuing Noncompliance>, <Suspension of IRB Approval> and <Termination of IRB Approval>
				10. Conduct independent IRB review to manage organizational conflict of interest related to the research.

The relying organization is responsible to identify organizational conflicts of interests.

* + - * 1. Identify and manage financial conflicts of interest of investigators and research staff and upon request, review and incorporate the relying organization’s management plan.
				2. Evaluate and confirm test articles have appropriate regulatory approval (e.g., IND or IDE, meet exemption requirements)

The relying organization is responsible to have and follow written policies and procedures to ensure that the handling of investigational or unlicensed test articles conforms to legal and regulatory requirements.

* + - * 1. Evaluate and permit emergency uses of a test articles and assure uses follow FDA requirements.
				2. Assure that emergency uses of a test articles are not considered <Human Research as Defined by HHS> and prohibit use of data obtained from an emergency use for <Human Research as Defined by HHS>.
				3. Assure investigators and research staff are trained on DOD requirements when research is DOD-regulated.
				4. Assure that IRB members, IRB Chairs and Vice Chairs are trained in accordance with applicable IRB SOPs on DOD requirements when research is DOD-regulated.
				5. Evaluate DOD research for scientific merit.
				6. For DOD research, determine that the investigator will follow all local laws, regulations, customs, and practices.
				7. Report serious or continuing noncompliance with DOD research to the DOD human research protection officer.
				8. For circumstances where DoD institutions rely on a collaborating non-DoD institution’s IRB ensure the following conditions are met:

Each institution engaged in non-exempt human participant research has a current federal assurance of compliance.

The non-DoD institution’s IRB is registered in accordance with Subpart E of 45 CFR 46.

The DoD institution reviews the protocol to ensure all applicable local and DoD requirements are addressed.

The DOD, non-DoD institutions, and the non-DoD institution’s IRB have a written agreement defining the responsibilities and authorities of each institution in complying with all legal requirements. This agreement specifies that the non-DoD IRB will apply the DoD requirements specified in DoDI 3216.02 including DoDI 3216.02 section 3.6(b).

* + - * 1. Assure all DOE requirements of 10 CFR 745 and DOE Order 443.1.B. are met.
				2. Assure all DOJ requirements of 28 CFR 22 and 512 are met.
				3. Evaluate DOJ research to assure there is an adequate research design and it contributes to the advancement of knowledge about corrections.
				4. Assure all ED requirements of 34 CFR 98, 99 and 356 are met.
				5. Assure EPA requirements of 40 CFR 26 and EPA Order 1000.17 Change A1 are met, and to flag research that collects data intended to be submitted to EPA as subject to EPA regulations.
				6. Determine if any additional approvals from DHHS and/or FDA are necessary when the research involves pregnant women, fetuses and neonates; or children; or prisoners and obtain such additional approvals as needed.
				7. Provide equivalent protections for participants in non-funded research.
				8. Ensuring concordance between any applicable grant in the IRB application, when required by regulators.
				9. Assure that investigators and research staff are appropriately trained.
				10. Facilitate cooperation of the researchers with the reviewing IRB’s or EC’s responsibility for initial and continuing review, record keeping, and reporting, and that all information requested by the reviewing IRB or EC must be provided in a timely manner.
				11. For international research:

Ensure appropriate expertise and knowledge of the country(ies) either through IRB members or consultants.

Ensure knowledge of local laws.

Ensure knowledge of cultural context.

Confirm the qualifications of the researchers and research staff for conducting research in that country.

Conduct initial review, continuing review, and review of amendments to previously approved research.

Conduct post-approval monitoring.

Handle complaints, noncompliance, and unanticipated problems involving risk to participants or others.

Manage consent process and document and other language issues.

Coordinate and communication with local IRBs when appropriate.

* + - * 1. Should the relying organization terminate reliance on the IRB, the IRB will continue oversight of active studies until closure or a mutually agreed-upon transfer of the studies.
		1. Upon request or when required by law, the [Organization] will execute an Authorization Agreement with the relying organization, which documents respective authorities, roles, responsibilities, sharing of records, and communication between this [Organization] and the relying organization.
		2. Investigators and research staff ultimately report to the [Organizational Official] for HRPP issues and are to follow the obligations described in “POLICY: Investigator Obligations (HRP-070).”
		3. The [Chief Research Compliance Officer] works with the [Organizational Official] on HRPP issues and is responsible to:
			1. Determine who is a <Legally Authorized Representative>, <Child>, and <Guardian>
			2. Provide legal advice related to the HRPP to the [Organizational Official], IRB, and investigators
			3. Determine who is an agent for purposes of engagement
			4. Identify relevant state and international laws
			5. Resolve conflicts among applicable laws
		4. Grants and Contracts Office works with the [Organizational Official] on HRPP issues.
			1. The Grants and Contracts Office is responsible to review contracts for compliance with HRPP requirements.
	1. Written Procedures
		1. The [Organization] makes written materials describing the HRPP available to all members of the [Organization] through its Website at <https://research.temple.edu/irb>.
		2. The [Organization] makes written materials describing the HRPP available to sponsors, CROs, relying institutions, and investigators upon request when those materials apply to the requestor.
		3. When written materials are changed, the [Organization] communicates to affected individuals through one or more of the following actions:
			1. Email communications
			2. Website postings
			3. Direct outreach at organizational meetings
			4. Training
			5. Mentoring
	2. <Reliance Agreements>
		1. For federally funded research that must follow the <Revised Rule> (with the exception of exempt research for which IRB review is not required by regulation) that takes place at an institution in which IRB oversight is conducted by an IRB that is not operated by the institution, the institution and the organization operating the IRB must document the institution’s reliance on the IRB for oversight of the research and the responsibilities that each entity will undertake—including additional certification requirements, (e.g. Certificates of Confidentiality, NIH Genomic Data Sharing Policy, etc.)—to ensure compliance with the requirements of this policy.
			1. If exceptions are made—by the funding federal agency (e.g. DOD, NIH, etc.)—to the single IRB requirement, these exceptions will be documented and stored.
			2. The requirement for single IRB review applies to awardees in the United States and participating research sites in the United States. The requirement for single IRB review does not apply to organizations outside the United States.
		2. When additional reviews relevant to the HRPP (including but not limited to: biosafety review, radiation safety review, recombinant DNA research review, human stem cell research review, and conflict of interest review) are required, the [Organization] will not rely on any external organizations or entities for those reviews that involve activities performed at the [Organization]. These reviews will be provided to the reviewing IRB when appropriate.
	3. Questions, Concerns, and Feedback
		1. The [Organization] solicits questions, concerns, and feedback by making the document “BROCHURE: Should I Take Part in Research (HRP-900)” available on its Web site and available to investigators to provide to the public.
		2. Individuals should address questions, suggestions, concerns, or complaints about the IRB, or human research protection program; allegations of undue influence, <Allegations of Noncompliance> or <Findings of Noncompliance> orally or in writing to:

|  |
| --- |
| IRB Office3340 North Broad Street, Suite 427Philadelphia, PA 19140Email: irb@temple.edu(215) 707-3390  |

* + 1. Individuals may also contact the [Organizational Official] at:

|  |
| --- |
| Joseph Gladden, Ph.D.Vice President for Research 1801 North Broad Street401 Conwell HallPhiladelphia, PA 19122joseph.gladden@temple.edu(215) 204-3708 |

* + 1. The [Organization] takes steps to protect employees and agents who report in good faith from retaliation and harassment. Immediately reports such concerns to the [Organizational Official].
		2. Individuals should address questions, suggestions, concerns, or complaints about the use of an external IRB orally or in writing to:

|  |
| --- |
| Director of Clinical Research3340 North Broad StreetPhiladelphia, PA 19140Email: IRB@temple.edu(215) 707-3390  |

1. REFERENCES
	1. “Ethical Principles and Guidelines for the Protection of Human Subjects of Research,” The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, April 18, 1979, (<http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html>)
	2. Table of Applicability of Regulatory and Policy Requirements by Category of Research

|  |  |
| --- | --- |
| Category of Research | Research initially reviewed, determined exempt, or waived: |
| Before Jan 21, 2019 | On or after Jan 21, 2019 |
| FDA regulated research that is NOT emergency use[[2]](#footnote-3), compassion use, or device research on anonymous tissue specimens[[3]](#footnote-4) | * FDA regulations
* <Original Rule>
* Subparts B, C, D
 | * FDA regulations
* <Original Rule>
* Subparts B, C, D
 |
| Emergency use, compassion use, and device research on anonymous tissue specimens[[4]](#footnote-5) | * FDA regulations
 | * FDA regulations
 |
| Research regulated by federal department or agency other than DOJ | * <Original Rule>[[5]](#footnote-6)
* Subparts B, C, D
 | * <Revised Rule>
* Subparts B, C, D
 |
| Research regulated by DOJ | * <Original Rule>
* Subparts B, C, D
 | * <Original Rule>
* Subparts B, C, D
 |
| Unregulated research not in NY, VA, or MD[[6]](#footnote-7) | * <Original Rule>[[7]](#footnote-8)
* Subparts B, C, D
 | * <Hybrid Rule>
* Subparts B, C, D
 |
| Unregulated research in NY, VA, MD[[8]](#footnote-9) | * <Original Rule>
* Subparts B, C, D
 | * <Revised Rule>
* Subparts B, C, D
 |

* 1. Table of Applicability of Regulatory and Policy Requirements by Requirement

|  |  |
| --- | --- |
| Requirement | Research initially reviewed, determined exempt, or waived: |
| Before Jan 21, 2019 | On or after Jan 21, 2019 |
| FDA regulations | * FDA regulated research
 | * FDA regulated research
 |
| <Original Rule> | * Research regulated by a federal department or agency
* FDA regulated research that is NOT emergency use, compassion use, or device research on anonymous tissue specimens
 | * Research regulated by DOJ
* FDA regulated research that is NOT emergency use, compassion use, or device research on anonymous tissue specimens
 |
| <Revised Rule>  | NA | * Research regulated by federal department or agency other than DOJ
 |
| <Hybrid Rule>  | NA | * Unregulated research[[9]](#footnote-10)
 |
| Subparts B, C, D | * All research except, emergency use, compassion use, and device research on anonymous tissue specimens[[10]](#footnote-11)
 | * All research except, emergency use, compassion use, and device research on anonymous tissue specimens
 |

1. OHRP has indicated that for research not conducted, supported, or otherwise subject to regulation by a federal department or agency, OHRP will not review reports (e.g., unanticipated problems, non-compliance, suspensions, terminations), will not provide secretarial review of not otherwise approvable research under Subparts B and D, and will not certify prisoner research under Subpart C. [↑](#footnote-ref-2)
2. This includes emergency use as defined in 21 CFR 56.102(d) and described in 21 CFR 50.23(a) and (b). This does not include waiver of consent for planned emergency research. [↑](#footnote-ref-3)
3. <Research Involving Human Subjects as Defined by FDA> that is also <Research Involving Human Subjects as Defined by HHS> [↑](#footnote-ref-4)
4. <Research Involving Human Subjects as Defined by FDA> that is NOT <Research Involving Human Subjects as Defined by HHS> [↑](#footnote-ref-5)
5. On or after January 21, 2019, sponsors can request that the research in this category initially reviewed, determined exempt, or waived before January 21, 2019 be re-reviewed under the <Revised Rule> [↑](#footnote-ref-6)
6. <Research Involving Human Subjects as Defined by HHS> that is NOT subject to regulation by either FDA or a federal department or agency [↑](#footnote-ref-7)
7. On or after January 21, 2019, sponsors can request that the research in this category initially reviewed, determined exempt, or waived before January 21, 2019 be re-reviewed under the <Hybrid Rule> [↑](#footnote-ref-8)
8. State law in New York (NY), Virginia (VA), and Maryland (MD) require application of state law unless the study is subject to and in compliance with the human subject protection regulations of any federal department or agency for the protection of human subjects. The [Institution] considers this research to be subject to HHS regulation by virtue of this policy to apply the <Revised Rule> to such research. [↑](#footnote-ref-9)
9. <Research Involving Human Subjects as Defined by HHS> that is NOT subject to regulation by either FDA or a federal department or agency [↑](#footnote-ref-10)
10. <Research Involving Human Subjects as Defined by HHS> including FDA regulated research that is also <Research Involving Human Subjects as Defined by HHS> [↑](#footnote-ref-11)